Challenges in the Use of Anthrax Vaccine Adsorbed (AVA) in the Pediatric Population as a Component of Post-Exposure Prophylaxis (PEP): A Report of the National Biodefense Science Board [open pdf - 816KB]
"In the event that Bacillus anthracis (B. anthracis) spores are released in the United States, the current plan of the U.S. Department of Health and Human Services (HHS) is to ensure that anthrax vaccine adsorbed (AVA) is made available to adults and children. In this emergency scenario, AVA would be offered in conjunction with antibiotics to prevent the development of infection and illness following exposure to anthrax spores, a form of therapy termed 'post-exposure prophylaxis' (PEP). The NBSB [National Biodefense Science Board] is a federal advisory committee authorized in December 2006 by the Pandemic and All-Hazards Preparedness Act (PAHPA). The NBSB provides expert advice and guidance to the Secretary of HHS, on scientific, technical, and other matters of special interest to HHS regarding current and future chemical, biological, radiological, and nuclear agents, whether naturally occurring, or accidentally or deliberately released. The NBSB also provides advice on issues related to public health emergency preparedness and response."
Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response: http://www.phe.gov